A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.

The revised nomenclature of metabolic dysfunction-associated steatohepatitis (MASH), rather than non-alcoholic steatohepatitis (NASH), appears to be taking hold among stakeholders in the liver disease space.

Akero’s Phase IIb study of FGF21 analog efruxifermin demonstrates long-term reduction or resolution of fibrosis, but concerns about bone mineral density declines may confound the data.

The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.